Physician profile
Beilan Zhou
NPI 1972976363
$3,713.47
in general payments reported to CMS, 2019-2025
33 companies · $621 in 2025
The $621 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $182 · 2021: $225 · 2022: $827 · 2023: $1,033 · 2024: $710 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $493.81 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $335.07 | 2023-2025 | Myfembree |
| Abbvie INC. | $287.02 | 2022-2023 | Lo Loestrin Fe, Orilissa |
| Bayer Healthcare Pharmaceuticals INC. | $217.67 | 2020-2025 | |
| Sage Therapeutics, LLC | $192.26 | 2021-2025 | Zurzuvae |
| Astellas Pharma US INC | $186.13 | 2022-2025 | Veozah |
| Exeltis, USA INC. | $165.92 | 2023-2025 | Slynd |
| Hologic Sales and Service, LLC | $164.60 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Myovant Sciences INC. | $152.69 | 2021-2022 | |
| Evofem Biosciences, INC. | $148.89 | 2021-2025 | Phexxi, Solosec, Phexx |
| Silk Road Medical, INC. | $133.20 | 2022 | |
| Organon LLC | $123.29 | 2021-2025 | Nexplanon |
| Medtronic, INC. | $116.70 | 2021-2024 | Truclear |
| Millicent US INC | $112.90 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Shield Therapeutics INC | $100.53 | 2023-2025 | Accrufer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.46 | 2021-2025 | |
| Acessa Health INC. | $84.58 | 2019 | |
| Novo Nordisk INC | $77.73 | 2024 | Wegovy |
| Mylan Pharmaceuticals INC. | $66.55 | 2020-2022 | |
| Avion Pharmaceuticals | $66.54 | 2020-2021 | |
| Lilly USA, LLC | $62.79 | 2025 | Zepbound |
| Agile Therapeutics, INC. | $46.85 | 2023-2024 | Twirla |
| Lupin INC. | $38.20 | 2020-2021 | |
| Aspira Women'S Health INC | $35.74 | 2022-2024 | Ova1 |
| Coopersurgical, INC. | $34.71 | 2020-2025 | Paragard T 380a |
| Therapeuticsmd, INC. | $31.60 | 2020-2022 | |
| Smith+Nephew, INC. | $26.62 | 2023 | Pico 7 |
| Myriad Women'S Health, INC. | $24.97 | 2023 | Myrisk |
| Medicem INC. | $22.24 | 2021 | |
| Dexcom, INC. | $20.90 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $19.14 | 2022 | |
| Merck Sharp & Dohme LLC | $16.91 | 2025 | Gardasil 9 |
| Optumhealth Care Solutions, LLC | $13.26 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beilan Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.